Skip to main content
  • Merck Drops Development of Once Promising CETP Inhibitor

    Merck announced on Wednesday that it would not seek regulatory approval for its cholesterol drug anacetrapib.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details